ATC codes
L Antineoplastic and immunomodulating agents
L01 Antineoplastic agents
L02 Endocrine therapy
L03 Immunostimulants
L04 Immunosuppressants
A • B • C • D • G • H • QI • J • L • M • N • P • R • S • V

ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.^[1]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: QL04...^[2]

Contents 1 L04A Immunosuppressants 1.1 L04AA Selective immunosuppressants 1.2 L04AB Tumor necrosis factor alpha (TNF-α) inhibitors 1.3 L04AC Interleukin inhibitors 1.4 L04AD Calcineurin inhibitors 1.5 L04AX Other immunosuppressants 2 References

[edit] L04A Immunosuppressants

[edit] L04AA Selective immunosuppressants

L04AA02 Muromonab-CD3

L04AA03 Antilymphocyte immunoglobulin (horse)

L04AA04 Antithymocyte immunoglobulin (rabbit)

L04AA06 Mycophenolic acid

L04AA10 Sirolimus

L04AA13 Leflunomide

L04AA15 Alefacept

L04AA18 Everolimus

L04AA19 Gusperimus

L04AA21 Efalizumab

L04AA22 Abetimus

L04AA23 Natalizumab

L04AA24 Abatacept

L04AA25 Eculizumab

[edit] L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

L04AB01 Etanercept

L04AB02 Infliximab

L04AB03 Afelimomab

L04AB04 Adalimumab

L04AB05 Certolizumab pegol

L04AB06 Golimumab

[edit] L04AC Interleukin inhibitors

L04AC01 Daclizumab

L04AC02 Basiliximab

L04AC03 Anakinra

L04AC04 Rilonacept

L04AC05 Ustekinumab

L04AC06 Mepolizumab

L04AC07 Tocilizumab

L04AC08 Canakinumab

[edit] L04AD Calcineurin inhibitors

L04AD01 Ciclosporin

L04AD02 Tacrolimus

[edit] L04AX Other immunosuppressants

L04AX01 Azathioprine

L04AX02 Thalidomide

L04AX03 Methotrexate

L04AX04 Lenalidomide

[edit] References

v • d • e Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04) Intracellular (signal initiation) Antimetabolites purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate Macrolides/ other IL-2 inhibitors FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus TNF-α inhibitor Thalidomide · Lenalidomide Intracellular (signal reception) IL-1 receptor antagonists Anakinra mTOR Sirolimus · Deforolimus · Everolimus · Temsirolimus · Zotarolimus · Biolimus A9 Extracellular Antibodies Monoclonal Serum target (noncellular) Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab)  · BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-13 (Lebrikizumab, Ustekinumab) Cellular target CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab) · CD154 (Ruplizumab) BLyS (Belimumab)  · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox) Unsorted Atorolimumab, Cedelizumab, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab Polyclonal Anti-thymocyte globulin · Anti-lymphocyte globulin -cept (Fusion protein) CTLA-4 (Abatacept, Belatacept) · Aflibercept · Alefacept · Rilonacept · TNF inhibitor (Etanercept)